Search results (1345)
« Back to PublicationsFLT3-ITD INDUCED MYELOPROLIFERATION CAUSES A CELL EXTRINSIC DEPLETION OF HAEMATOPOIETIC STEM CELLS
Mead AJ. et al, (2014), HAEMATOLOGICA, 99, 256 - 256
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.
Eyre TA. et al, (2014), Int J Hematol, 99, 798 - 800
OUTCOMES FOR MYELOFIBROSIS PATIENTS WHO SWITCHED FROM FEDRATINIB TO RUXOLITINIB THERAPY
Garcia NC. et al, (2014), HAEMATOLOGICA, 99, 670 - 671
T-cell/histiocyte-rich large B-cell lymphoma--transformation of nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow.
Eyre TA. et al, (2014), Eur J Haematol, 92, 550 - 551
A decision tree analysis of selective endoscopic ultrasound in staging oesophageal cancer
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 18 - 19
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG. et al, (2014), Lancet Oncol, 15, 620 - 630
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A. et al, (2014), Ann Oncol, 25, 968 - 974
Outcomes of adult patients undergoing autologous haematopoietic stem cell transplantation for T cell lymphoma in the Oxford region (1995-2012)
Sims MC. et al, (2014), BRITISH JOURNAL OF HAEMATOLOGY, 165, 101 - 102
Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.
Eyre TA. et al, (2014), Transfusion, 54, 1231 - 1234
The utility of restaging PET-CT In predicting progression to unresectable oesophageal cancer after neoadjuvant chemotherapy
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 19 - 19
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R. et al, (2014), Br J Dermatol, 170, 997 - 999
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
Hatch SB. et al, (2014), International Journal of Cancer, 134, 1495 - 1503
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB. et al, (2014), Int J Cancer, 134, 1495 - 1503
A STUDY OF THE EFFECT OF DABRAFENIB (D) AS AN INDUCER OF CYTOCHROME P450 (CYP) USING WARFARIN (W) AS A PROBE.
Carson SW. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S36 - S36
A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)
Suttle B. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S89 - S90
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M. et al, (2014), J Med Chem, 57, 1531 - 1542
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Valle JW. et al, (2014), J Clin Oncol, 32, 504 - 512
Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.
Grover A. et al, (2014), J Exp Med, 211, 181 - 188
Discovery of prognostic and predictive tissue biomarkers in patients with resectable esophageal cancer
MacGregor TP. et al, (2014), JOURNAL OF CLINICAL ONCOLOGY, 32